RGNX
Price
$14.95
Change
-$0.10 (-0.66%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
756.82M
47 days until earnings call
Intraday BUY SELL Signals
TBPH
Price
$20.61
Change
+$0.28 (+1.38%)
Updated
Jan 14 closing price
Capitalization
1.04B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RGNX vs TBPH

Header iconRGNX vs TBPH Comparison
Open Charts RGNX vs TBPHBanner chart's image
REGENXBIO
Price$14.95
Change-$0.10 (-0.66%)
Volume$5.03K
Capitalization756.82M
Theravance Biopharma
Price$20.61
Change+$0.28 (+1.38%)
Volume$306.88K
Capitalization1.04B
RGNX vs TBPH Comparison Chart in %
RGNX
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RGNX vs. TBPH commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and TBPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (RGNX: $15.05 vs. TBPH: $20.33)
Brand notoriety: RGNX and TBPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 78% vs. TBPH: 70%
Market capitalization -- RGNX: $761.88M vs. TBPH: $1.03B
RGNX [@Biotechnology] is valued at $761.88M. TBPH’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileTBPH’s FA Score has 0 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • TBPH’s FA Score: 0 green, 5 red.
According to our system of comparison, RGNX is a better buy in the long-term than TBPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 4 TA indicator(s) are bullish while TBPH’s TA Score has 3 bullish TA indicator(s).

  • RGNX’s TA Score: 4 bullish, 3 bearish.
  • TBPH’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than TBPH.

Price Growth

RGNX (@Biotechnology) experienced а +6.14% price change this week, while TBPH (@Biotechnology) price change was +11.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

RGNX is expected to report earnings on Mar 03, 2026.

TBPH is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TBPH($1.05B) has a higher market cap than RGNX($757M). TBPH YTD gains are higher at: 8.658 vs. RGNX (4.514). TBPH has higher annual earnings (EBITDA): 53.1M vs. RGNX (-120M). TBPH has more cash in the bank: 330M vs. RGNX (274M). TBPH has less debt than RGNX: TBPH (44.6M) vs RGNX (76.5M). RGNX has higher revenues than TBPH: RGNX (161M) vs TBPH (80.3M).
RGNXTBPHRGNX / TBPH
Capitalization757M1.05B72%
EBITDA-120M53.1M-226%
Gain YTD4.5148.65852%
P/E RatioN/A36.18-
Revenue161M80.3M200%
Total Cash274M330M83%
Total Debt76.5M44.6M172%
FUNDAMENTALS RATINGS
RGNX vs TBPH: Fundamental Ratings
RGNX
TBPH
OUTLOOK RATING
1..100
6827
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
9856
PRICE GROWTH RATING
1..100
3737
P/E GROWTH RATING
1..100
2385
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (75) in the Biotechnology industry is in the same range as TBPH (79) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew similarly to TBPH’s over the last 12 months.

TBPH's Profit vs Risk Rating (96) in the Pharmaceuticals Other industry is in the same range as RGNX (100) in the Biotechnology industry. This means that TBPH’s stock grew similarly to RGNX’s over the last 12 months.

TBPH's SMR Rating (56) in the Pharmaceuticals Other industry is somewhat better than the same rating for RGNX (98) in the Biotechnology industry. This means that TBPH’s stock grew somewhat faster than RGNX’s over the last 12 months.

TBPH's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as RGNX (37) in the Biotechnology industry. This means that TBPH’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (23) in the Biotechnology industry is somewhat better than the same rating for TBPH (85) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew somewhat faster than TBPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXTBPH
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 13 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGOVX82.460.15
+0.18%
Hartford Growth Opportunities R6
IIVAX26.880.04
+0.15%
Transamerica Small/Mid Cap Value A
FIJYX40.71N/A
N/A
Fidelity Advisor Biotechnology Z
SBIYX13.84-0.04
-0.29%
ClearBridge International Value I
HEQCX5.61-0.03
-0.53%
Monteagle Opportunity Equity Instl

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-0.20%
SYRE - RGNX
56%
Loosely correlated
-3.87%
BEAM - RGNX
55%
Loosely correlated
+2.55%
VYGR - RGNX
55%
Loosely correlated
+3.08%
XNCR - RGNX
54%
Loosely correlated
-1.62%
DNLI - RGNX
52%
Loosely correlated
+0.89%
More

TBPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with KYMR. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
+3.46%
KYMR - TBPH
40%
Loosely correlated
+1.42%
VYGR - TBPH
40%
Loosely correlated
+3.08%
TARA - TBPH
38%
Loosely correlated
-6.11%
RGNX - TBPH
37%
Loosely correlated
-0.20%
VERA - TBPH
36%
Loosely correlated
+5.68%
More